Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multi-center phase 1 study. The trial, consisting of Part 1a dose confirmation and Part 1b dose expansion, is designed to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in combination with pembrolizumab in patients with advanced NSCLC and other solid tumors.

Clinical Trial Description

subjects will be treated with HBM4003 in combination with pembrolizumab for up to 2 years or until confirmed disease progression, unacceptable tolerability or treatment discontinuation through withdrawal of consent occurs, whichever happens first. This trial consists of : - A screening period: 28 days - A treatment period: - Part 1a dose confirmation study - Part 1b dose expansion study - A post-treatment follow-up period, including - A safety follow-up period: 28 days after the last dose of study drug; - Post-treatment follow-up visit: day 84 after the last dose of study drug; - Survival follow-up. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04866485
Study type Interventional
Source Harbour BioMed (Guangzhou) Co. Ltd.
Contact Xi LIU
Phone +8618616529165
Email [email protected]
Status Not yet recruiting
Phase Phase 1
Start date June 14, 2021
Completion date February 2023

See also
  Status Clinical Trial Phase
Recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Active, not recruiting NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Recruiting NCT04553692 - Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers Phase 1
Recruiting NCT04096638 - Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04180384 - A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients Phase 2
Recruiting NCT04673396 - Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor Phase 1
Recruiting NCT04475523 - Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies Phase 1
Not yet recruiting NCT04683939 - Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 Phase 1/Phase 2
Not yet recruiting NCT04569916 - Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors Phase 2
Terminated NCT02737072 - A Study of LY2510924 and Durvalumab in Participants With Solid Tumors Phase 1
Terminated NCT02653196 - A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors Early Phase 1